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1. Introduction
Targeted medical intervention for the treatment of rheumatoid arthritis (RA) has significantly
revolutionized clinical outcomes for this autoimmune disease. Until the development of
biological drugs which have the capacity to block the activity of most of the critical pro-
inflammatory cytokines involved in RA as well as a host of immune cell-mediated events, the
medical therapy of RA was limited to the use of first-line treatments including, non-steroidal
anti-inflammatory drugs, sulphasalazine, and several immunosuppressive agents, such as
glucocorticoids, prednisone and dexamethasone, methotrexate, and anti-malarial drugs (e.g.
hydroxychloroquine) [1-5]. Agents that blocked the proliferation of T-lymphocytes, such as
leflunomide, abatacept and/or B-lymphocytes (e.g. rituximab) were also employed, but mainly
as second-line therapies [6-9].
The momentous development of additional biological drugs for RA arose through the
identification of those pro-inflammatory cytokines that were intimately involved in initiating
and perpetuating the RA process. Thus, blocking tumor necrosis factor-α/tumor necrosis
factor-α receptor, interleukin-1β (IL-1β) IL-1β receptor and IL-6/IL-6 Receptor/gp130 signaling
pathways with either monoclonal antibodies or engineered fusion proteins prominently
entered into the armamentarium for the medical therapy of RA [10-15].
However,  what  does  all  of  this  mean  for  the  future  development  of  additional  novel
therapies  for  this  chronic  and  debilitating  synovial  joint  disease?  For  one  thing  the
revolution  in  new  drug  development  implies  that  although  additional  cellular  targets
including vascular endothelial growth factor (VEGF), adhesion molecules (e.g. vascular cell
adhesion  molecule-1;  VCAM-1;  CD106)  and  chemokines  (e.g.  CXC,  C,  CX3C  and  their
corresponding receptors, CXCR, CCCR, CR and CX3CR) [16-26] which fit securely into a
system of  well-orchestrated RA pathophysiologic  processes  in  man have been validated
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through in vitro  studies as well as from impressive clinical results and ex vivo  cell analy‐
ses  with  rodent  models  of  human  RA.  Although  none  of  the  CC  chemokine  receptor
antagonists have thus far yielded drugs effective in a rheumatology clinical practice, there
are CXCR4 small drug antagonists in clinical trials for cancer, human immunodeficiency
virus and the rare WHIM immunodeficiency condition [27].
One aspect in the study of human RA progression revolves around successfully translating
from “hypothesis” to experimental validation and then going forward to drug development.
This advancement has occurred by recognizing the crucial role played by signal transduction
pathways in perpetuating the inflammatory state of RA. Thus, signal transduction has also
been identified as the crucial cellular pathway that can cause “apoptosis-resistance” resulting
in the aberrant survival of activated T-lymphocytes, B-lymphocytes and synoviocytes in RA
synovial tissue [28, 29]. Signal transduction has also been identified as playing a role in the
elevated frequency of apoptotic chondrocytes in RA articular cartilage [30, 31]. In that regard,
blocking the phosphorylation of specific protein kinases involved signal transduction was
explored as a mechanism to not only restore the appropriate balance between cell survival and
cell death, which is skewed towards cell survival in RA, but also for blocking those protein
kinases involved in up-regulating pro-inflammatory cytokine and matrix metalloproteinase
(MMP) gene expression that is so integral to perpetuating inflammation and therefore, the
destruction of synovial joints in RA [32-36].
Over the past 8 years or so, we have extensively detailed the genesis of interest in, and the
extent to which, kinase activity of mitogen-activated protein kinases (MAPK) and the phos‐
phatidylinositide-3-kinase/AKT/mammalian target of rapamycin (mTOR) (PI3K/AKT/mTOR)
pathways influence MMP gene expression and cell survival, respectively [37-41]. We and
others have also focused attention on the Janus Kinase/Signal Transducers and Activators of
Transcription (JAK/STAT) pathway which was identified and targeted for drug development
in RA because JAK/STAT signaling was found to play a major role in RA by promoting pro-
inflammatory cytokine gene expression and abnormal cell survival [42-48]. Thus, this latter
research focus resulted in the first JAK3-selective small molecule inhibitor (SMI), tofactinib,
for use in the treatment of RA [reviewed in 49, 50].
This chapter will critically analyze the current state of drug development for novel protein
kinase SMIs for RA, including a brief update and perspective on newer JAK SMI, besides
tofacitinib, which are likely to be the targets for future drug development as well as additional
protein kinase targets for RA.
2. Newer JAK SMIs
There are 4 members of the JAK family: JAK1, JAK2, JAK3 and Tyk2 [51]. JAK1 and JAK3 bind
constitutively to the cytoplasmic region of the common gamma chain of cytokine receptors.
This domain is the common subunit for many cytokines involved in T-cell and natural killer
cell development in addition to B-cell activation making JAK1/JAK3 pertinent targets for
intervention in RA [47, 52]. In addition to the JAK3-selective SMI, tofacitinib [54], several other
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JAK SMIs, with activity towards JAK 1 and JAK2, including baricitinib [55], CEP-33779 [55],
INCB028050, PF-956980 [56, 57], filgotinib (INCB-039110), decernotinib, ruxolitinib, pefcitinib,
ABT-494, INCB 047986 and AC-410 [58] are currently in various stages of preclinical testing
and/or clinical assessment for altering the clinical course of RA, organ transplant rejection and
psoriasis [59].
It has been widely held that JAK1 and JAK3 are essentially regulated by specific tyrosine sites
within their respective activation loops [60], including the NH2-terminal kinase domain [45].
As such the activity of both JAK1 and JAK3 need be blocked to ensure inhibition of IL-2-
induced STAT5 activation [47]. This assertion is bolstered by evidence that JAK1 has a
dominant role over JAK3 [61] likely making selective ATP-competitive JAK3 inhibitors less
effective by themselves at the cellular level. Thus, the targeting of suppressor of cytokine
signaling as a means to suppress JAK/STAT signaling [45, 62, 63] is also being investigated for
its potential to block cytokine-mediated STAT activation.
3. Update on tofacitinib — 2014
The approval of tofacitinib by the United States Food & Drug Administration in 2012 for the
treatment of moderate-severe RA has paved the way for the development of other JAK
inhibitor compounds [64, 65]. The clinical data emerging from 4 Phase II and 4 Phase III RA
clinical trials involving tofacitinib was recently summarized [Malemud CJ: Submitted]. In the
Phase III RA trials where tofacitinib was compared to placebo a significant American College
of Rheumatology-20 (ACR20) response was consistently demonstrated in the tofacitinib arm
together with an improvement in the Health Assessment Questionnaire Disability Index and
ACR50 response after 3 months of treatment with tofacitinib [66]. Most critically, these Phase
III trials demonstrated that the clinical efficacy of tofacitinib was similar to the clinical
responses achieved with the TNF inhibitor, adalimumab. Several common adverse events
observed in these clinical trials were associated with the tofacitinib group and raised some
concerns. This included an increase in the incidence of infections, infestations and creatinine
along with an increase in the LDL-cholesterol/HDL-cholesterol ratio and decreased neutrophil
counts. However, a recent meta-analysis of various RA clinical trials involving tofacitinib
concluded that the frequency of adverse events was not increased by tofacitinib [67].
In another clinical trial where the clinical efficacy of tofacitinib was compared to methotrexate
[68], 3 cases of confirmed lymphoma in 5 patients receiving tofacitinib compared to 1 subject
in the methotrexate arm was reported. However, the ACR70 response was greater in the
tofacitinib group compared to methotrexate, but the mean change in number of bone erosions
in both the tofacitinib and methotrexate groups was modest. Importantly the subjects receiving
tofacitinib had less cartilage loss at 6, 12 and 24 months of treatment.
Malemud and Blumenthal [50] recently reviewed the variety of cellular mechanisms that have
been shown to be altered by tofacitinib which likely contributed to the clinical efficacy of the
drug in human RA clinical trials, including the relative selectivity of tofacitinib for JAK1 and
JAK3 over JAK2 in ameliorating the severity of arthritis in the rat-adjuvant model [69] as well
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as data showing that multiple cytokines and signaling pathways in addition to JAK/STAT were
inhibited by tofacitinib at effective clinical doses which was distinct from conventional disease-
modifying antirheumatic drugs [70].
Although it is expected that the efficacy of tofacitinib in rheumatology clinical practice will
have to be continuously monitored, tofacitinib will likely emerge as an important option for
RA patients who inadequately respond to low-dose glucocorticoids, methotrexate and the
several biologic drugs that are now routinely prescribed for the management of moderate-to-
severe RA [50, 71, 72].
4. Selective JAK inhibitors in development
4.1. Baricitinib
Baricitinib (alternatively known as 1187594-09-7; INCB028050; UNII-ISP444213Y; LY3009104;
LY-3009104 (Figure 1) [72] is a novel orally administered JAK inhibitor compound with relative
selectivity for JAK1 and JAK2 [74]. In a study conducted among normal volunteers, baricitinib
showed a dose-linear and time variant pharmacokinetics with low oral-dose clearance (i.e.
17L/h) and minimal systematic accumulation. Baricitinib also inhibited STAT3 phosphoryla‐
tion in whole blood ex vivo, the results of which correlated with plasma concentrations of the
drug. Although baricitinib was well-tolerated with negligible adverse events, the expected
reduction in neutrophil counts was also recorded [75].
Figure 1. The chemical structure (IUPAC Name) of 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-
yl]azetidin-3-yl]acetonitrile (Baricitinib) [73]
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4.2. Decernotinib
Decernotinib (Figure 2) alternatively known as VX-509, is an orally administered selective
JAK3 inhibitor compound which is being evaluated for the possible medical management of
RA [58, 76]. In a recently completed study the results of which were reported at the 2014
European League Against Rheumatism (EULAR) annual meeting, the pharmacologic activity
of decernotinib was compared to tofacitinib, filgotinib (GLPG 0634) and baricitinib with
reference to the blockade of several cytokine signaling pathways in whole blood cell cultures
from normal subjects. The cytokine pathways evaluated were the type I and type II interferon
(i.e. INFα and INFγ) pathways, the common γ chain cytokine pathways involving IL-15 and
IL-21, and the IL-6 and IL-27-mediated signaling [77]. Although the results of this study
showed that each of the JAK inhibitor compounds were relatively similar to each other in terms
of their ability to block INFα and INFγ, IL-15, IL-21, IL-6 and IL-27 signaling, tofacitinib and
baricitinib were more potent than decernotinib and filgotinib. Of note, these JAK inhibitor
compounds exhibited lesser activity towards IL-10, IL-12, IL-23 and erythropoietin, which also
signal via JAK/STAT [45]. Moreover, the results of the ex vivo studies evaluating the effect of
these JAK inhibitor compounds on inhibition of cytokine signaling showed that they had
markedly similar activities at clinically relevant doses.
Figure 2. The chemical structure (IUPAC Name) of disodium N2-[2-(1H-Pyrrolo[2,3-pyridin-3-yl)pyrimidin-4-yl]-N-
(2,2,2-trifluoroethyl)-D-isovalinamide (Decernotinib) [76]
A recently completed 24-week randomized, placebo-controlled, double-blind, phase II study
compared 4 dosing regimens of orally administered decernotinib given to 358 active RA
patients, measured by increased C-reactive protein levels and in RA patients with at least 6
swollen and 6 tender joints who had an inadequate clinical response to methotrexate [78]. After
24 weeks, the clinical response to decernotinib was statistically significant by ACR20, ACR50
and ACR70 criteria and by positive changes in the Disease Activity Score-28 outcomes
measure. However, the percentage of patients with any adverse event was higher in the
decernotinib arm relative to placebo (i.e. a stable dose of methotrexate) which led to 9.1% of
patients in the decernotinib group and 8.5 patients in the placebo group, respectively, to
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discontinue treatment. Of note, safety profiles were comparable across all dosage levels of
decernotinib.
5. Compounds that inhibit TyK2
Tyrosine kinase-2 (TyK2) is the fourth member of the Janus kinase family. However, the
development of TyK2-selective SMIs has lagged significantly behind the development of SMIs
with activity against the other 3 members of the JAK family [79, 80]. Thus, this remains an
ongoing controversy for developing additional small compounds for RA despite the purported
critical importance of TyK2 in driving IL-12-related cytokine IL-23 signaling which plays a key
role in RA [81, 82].
In RA IL-23 is widely recognized as a key cytokine because of its role in perpetuating the
inflammatory response as well as its involvement in the development of the IL-17-produc‐
ing  TH17  T-cell  subset,  the  latter  developing  as  a  distinct  T-cell  lineage  apart  from the
cytokine-producing TH1 and TH2 T-cells [82].  Although the IL-23 receptor was the initial
potential target for intervention in RA, inflammatory bowel disease, psoriasis and multi‐
ple sclerosis [83], a few laboratories focused on designing and synthesizing diamino 1, 2,
4 triazole compounds which could potentially demonstrate differential inhibition of TyK2
and JAKs 1-3 [81] or small molecule compounds such as APY0201 which was reported to
directly inhibit IL-23 production [84].
Until recently, there were no patents filed for the design or production of selective TyK2
inhibitors. In that regard, both tofacitinib and one other small molecule compound, CMP6,
failed to markedly inhibit TyK2. However, results with another small molecule compound,
Cmpd1, showed some promise in preclinical analyses [85, 86]. For example, Qi et al. [87]
recently demonstrated in human cervical cancer HeLa cells that apoptosis was enhanced after
incubation of these cells with TNF-α but only if TNF-α-induced heat shock protein (HSP)27
phosphorylation was suppressed by Cmpd1, or by MAPKAPK2 knockdown or by overex‐
pression of a non-phosphorylatable HSP27 mutant, HSP27-3A. Thus, these results reported
for Cmpd1 could indicate a role for TyK2 inhibition as influencing apoptosis in HeLa which
may be useful to “cure” the apoptosis-resistance characteristic of RA synovial tissue [88].
However, in that study, HSP27 phosphorylation also facilitated TNF-α ubiquitination and
phosphorylation of TAK1 as well as activation of p38 MAPK and ERK, the TAK1 pro-survival
pathway downstream of p38 MAPK and ERK. Therefore, the extent to which further devel‐
opment of TyK2 small molecule inhibitor compounds such as Cmpd1 go forward will likely
depend on its capacity to alter arthritis severity in rodent animal models of RA which will be
solely dependent on the design and successful synthesis of selective TyK2 SMIs.
6. The spleen tyrosine Kinase (SyK) inhibitor, fostamatinib
SyK and the ζ-chain associated protein-70 (ZAP-70) are non-receptor kinases which are
preferentially produced by hemopoietic cells of the spleen, mast cells, polymorphonuclear
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leukocytes and macrophages [89]. In the context of adaptive immunity relevant to RA, Syk
and ZAP-70 are major components in T-cell and B-cell receptor signaling [90]. Based on those
findings, Syk was considered to be a promising target for RA primarily because of its involve‐
ment in regulating, not only T-cell and B-cell proliferation as well as those proliferating cells
with the Fγ-activating receptor, but also in mediating immunoreceptor signaling by inflam‐
matory cells and in signaling pathways regulated by immune complexes [91, 92].
Several years ago, Pine et al [93] showed that R788, which is the prodrug of the novel SyK SMI,
R406, suppressed the severity of arthritis in collagen-induced arthritis (CIA), a well-validated
mouse model of human RA. In addition to the finding that R788 showed significant clinical
efficacy in mouse CIA, several surrogate molecules known to play important roles in inflam‐
matory arthritis, namely the CXCR2 ligand KC-GRO-α, macrophage chemoattractant pro‐
tein-1, IL-1 and IL-6 were also reduced in mice with CIA treated with R788 compared to the
vehicle control. Of note, the release of cartilage oligomeric matrix protein (COMP), a biomarker
of extracellular matrix degradation in articular cartilage, was also suppressed by R788
suggesting a possible chondroprotective effect of R788.
More recent studies have been conducted to assess the pharmacokinetic/pharmacodynamic
(PKPD) of R788, alternatively known as Fostamatinib disodium; R935788; R 935788 sodium;
FosD, tamatinib fosdium (Figure 3) [94]. Results of these studies revealed that the converted
form of the drug, R406, exhibited a PKPD relationship with changes in blood pressure [95].
Thus, the PKPD analysis revealed a concentration-dependent increase in blood pressure with
increasing concentrations of R406. Nevertheless Baloum et al. [96] showed that R406 was
rapidly absorbed with a terminal t1/2 of 12-21 hrs. Furthermore, the solid dosage forms of
fostamatinib provided a drug administration regimen whereby fostamatinib could be admin‐
istered once daily or twice daily to achieve therapeutic levels of the drug.
What additional parameters of adaptive immunity were found to be altered by fostamatinib?
Although R406 reduced the responsiveness of dendritic cells to immune complexes adminis‐
tered to mice, R406 did not reduce specific CD4+T-cell proliferation in these mice after
immunization with these immune complexes [97]. However, R406 did reduce the interactions
that occur between dendritic cells and antigen-specific CD4+T-cells. This resulted in reduced
proliferation of these antigen-specific CD4+T-cells compared mice treated with the vehicle
control. This change in antigen-specific CD4+T-cell proliferation in response to R406 was also
characterized by a reduction in the level of several T-cell co-stimulatory biomarkers, namely,
inducible T-cell co-stimulator and PD-1 as well as diminished production of the pro-inflam‐
matory cytokines, INF-γ and IL-17. Taken together, these ex vivo results provided additional
support for the indication that inhibiting SyK activity with fostamatinib could be an effective
drug therapy to eliminate FcR-driven CD4+T-cells responses in RA.
So how did fostamatinib fare in RA clinical trials? The results of several RA clinical trials
assessed the clinical efficacy of fostamatinib [98, 99]. Thus, Taylor et al. [98] reported that
treatment of moderate-severe RA subjects with fostamatinib improved the DAS-28/C-reactive
protein (CRP) score from baseline versus placebo injection at 6 wks at 2 dosage regimens: 100
mg twice daily for 24 wks plus placebo injection every 2 wks and 100 mg twice daily for 4 wks,
followed by 150 mg once daily up to wk 24. However, DAS-28/CRP failed to improve when
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fostamatinib was administered at 100 mg twice daily for 4 wks, then 100 mg once daily up to
wk 24. Most critically, in a comparator analysis, fostamatinib was less effective than the TNF-
α blocker, adalimumab, at wk 24 based on the DAS-28/CRP criteria. The most common adverse
effects of fostamatinib in this clinical trial were similar to those previously reported which
included increased hypertension and diarrhea. Thus, although fostamatinib demonstrated
significant clinical efficacy when employed as a monotherapy using DAS-28/CRP criteria at 6
wks, fostamatinib was inferior to adalimumab at wk 24.
Three additional RA clinical trials measured the effectiveness of fostamatinib on subchondral
bone erosions using the modified total Sharp score as an indicator of whether inhibition of SyK
retarded the destruction of subchondral bone over a period of 6 months. ACR response criteria
were also measured [99]. Once again, hypertension was the most relevant adverse event
affecting 40% of fostamatinib-treated subjects with other common negative responses,
including, diarrhea, neutropenia and increased hepatic enzyme levels. Some of the fostama‐
tinib-treated RA subjects also developed infections. Most critically, although RA subjects
treated with fostamatinib showed a positive clinical response by ACR criteria, none of the 3
clinical trials revealed any significant effects on erosive bone damage over the 6 months of
treatment.
Although SyK was shown to play an influential role in regulating the aberrant proliferation of
several immune cell types critical to the RA process in vitro and ex vivo, the results of several
RA clinical trials with fostamatinib were not impressive enough to warrant further develop‐
ment of this SyK SMI for RA.
Figure 3. The chemical structure (IUPAC Name) of [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-
dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate (Fostamatinib Sodium) [94]
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7. A perspective on the future development of protein kinase SMIs for RA
The current state of affairs regarding the future development of additional protein kinase small
molecule compounds for the treatment of RA should arise from the paradigm employed that
ultimately led to the US FDA approving tofacitinib for moderate-to-severe RA. An assessment
of the extent to which tofacitinib would be regularly prescribed for the treatment of RA recently
concluded that most-marketing surveillance data will ultimately determine the extent to which
tofacitinib will only be used to treat RA patients with inadequate responses to conventional
DMARDs and/or the several types of biologic drugs now available to treat RA or whether
tofacitinib will be employed as a first-line therapy for RA [50]. Although this assertion appears
to have some validity based on the current thinking by rheumatologists regarding the use of
tofacitinib, decisions must be made by the biopharmaceutical industry as to whether to
develop other JAK SMIs for future therapy of autoimmune diseases. Some of these newer small
molecule compounds were shown to inhibit JAK1 and JAK3, whereas others may be designed
to selectively inhibit JAK2. In that respect, the structure of the JAK3 enzyme may be instructive
(Figure 4). It was recently pointed out that tofacitinib was originally introduced as a JAK3-
selective SMI, but in reality tofacitinib also inhibits JAK1 and JAK2 [100]. In addition, Chrencik
et al. [101] indicated that computational analysis comparing tofacitinib with the TyK2 SMI,
CMP-6, showed that kinome-selectivity will be a challenge as a consequence of the overall
similarities in structure between JAKs 1-3 and TyK2, as well as the fact that the JAK3 SMI binds
to the ATP-binding cavities in an orientation which is similar to JAK1 and JAK2. Therefore,
the jury is still out, so to speak, as to whether or not immune-mediated inflammation and other
pathophysiologic abnormalities associated with aberrant JAK/STAT signaling in RA can be
regulated by focusing on developing a JAK SMI specific for a single member of the JAK family
or whether small molecule compounds which are designed to inhibit more than one JAK form
would be a more effective RA therapy.
Figure 4. The JH domains and phosphorylation sites of JAK3 [45]
The drug armamentarium for treating RA now include, immunosupressants such as metho‐
trexate, as well as immunomodulatory drugs which block TNF-α, anti-IL-1, and T-and B-cell
activation among other pathways. Therefore the extent to which JAK and/or SyK inhibitors
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will be employed with equal footing to these well-established drugs with clinical efficacy for
RA remains to be determined.
Then there is a host of data that supports a role for other protein kinases in the RA process.
However, it can be stated at this time that the results of preclinical and RA clinical trials
analyses are more compelling for developing small molecule compounds to inhibit TyK2 than
SyK.
Recently, we pointed out that in addition to JAK, TyK2 and SyK, it may be prudent for
investigators to consider the role that abnormalities play in other signal transduction pathways
associated with RA as future targets for therapeutic intervention [40]. The data supporting a
robust level of “cross-talk” between several signaling pathways that contribute to cytokine,
matrix metalloproteinase, pro-apoptosis and anti-apoptosis gene expression is well-proven
[28, 29, 35, 40, 41] and should be taken into account. In that regard, aberrations found in RA
in the PI3K/Akt/mTOR pathway, transforming growth factor kinase-1, bone marrow kinase,
nuclear factor κB-inducing kinase and Bruton’s tyrosine kinase could become a focus of future
small molecule inhibitor drug development.
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